BioSpace News Archive

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1.

Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global

Calyx / Invicro, a global leader in providing medical imaging solutions and development services to the clinical research community, announces a strategic partnership with BAMF Health, a world leader in molecular imaging and theranostics.

Vera Therapeutics, Inc. announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units for 14,500 shares of Class A common stock to five new employees under Vera’s 2024 Inducement Plan.

Structure Therapeutics Inc. announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares, each representing three ordinary shares, including the full exercise of the underwriters’ option to purchase up to 1,360,045 additional ADSs, at a public offering price of $52.50 per ADS.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.

ORIC Pharmaceuticals, Inc. announced that on June 3, 2024, ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”), today announced that it is undertaking a private placement of unsecured debenture units.

Principle Diagnostics Laboratory, a leader in Pharmacogenomic testing, proudly celebrates a decade of pioneering advancements in personalized medicine.

STRATA Skin Sciences, Inc. announces the publication of a clinical study titled, " A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne in Healthy Adolescents and Young Adults,” in the June 2024 issue of the Journal of Clinical and Aesthetic Dermatology.